India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain

Pfizer’s Sasanlimab in combination with BCG improves survival in patients with bladder cancer

If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population

Gen Z split on AI as global study reveals rising tech optimism

Health innovations are viewed more positively than food and agricultural technologies

ImmunityBio scores first Asian approval for ANKTIVA in Macau

The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency

Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer

The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients

ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients

To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia

Alkem MedTech to acquire 55% stake in Switzerland's Occlutech for €99.4M

Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure

Boehringer Ingelheim and Jazz Pharma team up on novel HER2-positive breast cancer therapy

The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial

FDA endorses Relmada’s registrational strategy for bladder cancer therapy

ImmunityBio’s ANKTIVA wins EMA nod for early EU approval in hard-to-treat bladder cancer